drugset / Trial / NCT00433199

Testosterone Treatment for Hypogonadal Men

NCT00433199

Phase 3 Completed 274 enrolled Abbott
RandomizedParallel-groupTriple-blindTreatment

Summary

Demonstrate efficacy and safety of Testosterone Gel 1.62% for the treatment of hypogonadal men

Timeline

Start
2007-02
Primary completion
2007-10
Completion
2008-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Testosterone Small molecule 1.62 % Topical

Indications